Introduction
============

Hip fracture is a frequent surgical procedure among the elderly.[@b1-clep-10-1053] It correlates with high medical costs and health care utilization[@b2-clep-10-1053] and confers increased risk of mortality.[@b3-clep-10-1053] Thirty-day mortality in elderly surgically treated hip fracture patients is 10% and increases to 30% within 1 year.[@b4-clep-10-1053] Patients who receive the recommended pre- and postoperative in-hospital care such as pain assessment, nutritional risk assessment, osteoporosis prophylaxis, and basic mobility assessment at admission and discharge may have a lower mortality risk compared with those who do not.[@b5-clep-10-1053] Additionally, high mortality is linked to the occurrence of postoperative complications, which affect \~20% of elderly hip fracture patients.[@b5-clep-10-1053],[@b6-clep-10-1053] The most common postoperative complication is infection.[@b4-clep-10-1053] However, patients can experience venous thromboembolism (VTE), myocardial infarction (MI), stroke, and gastrointestinal bleeding as well.[@b4-clep-10-1053],[@b7-clep-10-1053]

Elderly hip fracture patients are often multimorbid and receive multiple prescription medications including selective serotonin reuptake inhibitors (SSRIs).[@b8-clep-10-1053] SSRIs are prescribed to 10% of Danish elderly aged 65 years or older.[@b9-clep-10-1053] The most common indications for SSRI prescribing are depression and anxiety.[@b10-clep-10-1053] In general, SSRI use appears to increase the risk of mortality, new cardiovascular events, and postoperative bleeding.[@b6-clep-10-1053],[@b11-clep-10-1053] Previous studies among patients undergoing major surgery, including orthopedic surgeries, reported higher risk of mortality, readmission, and blood transfusion in those using SSRIs perioperatively.[@b12-clep-10-1053],[@b13-clep-10-1053] However, a study including orthopedic patients showed no evidence that SSRI use increased the risk of receiving a blood transfusion.[@b14-clep-10-1053] Thus, existing literature examining the effect of SSRI use on surgery outcome is somewhat inconclusive. The impact of preadmission SSRI use on mortality, postoperative complications, and quality of in-hospital care among elderly and fragile hip fracture patients has not been reported previously. Therefore, we conducted a nationwide, prospective cohort study examining whether preadmission SSRI use is associated with adverse outcomes in hip fracture surgery patients.

Ethics approval
===============

Ethical approval was not required according to the Danish Act on Research Ethics Review of Health Research Projects due to the register-based nature of the study. The study was approved by the Danish Data Protection Agency (record number: 1-16-02-467-15).

Patients and methods
====================

Setting and design
------------------

The study is a nationwide cohort study using prospectively collected data from Danish medical registries covering all Danish citizens; approximately 5.7 million people.[@b15-clep-10-1053] The health care system in Denmark is tax-funded, and all citizens have equal access to health care services.

Data sources
------------

The Danish Multidisciplinary Hip Fracture Registry[@b16-clep-10-1053] has routinely registered comprehensive clinical data on all patients aged 65 years or older with first-time hip fracture admitted to any orthopedic department in Denmark since 2004. Data include detailed pre- and postoperative data, as well as data on quality of in-hospital care represented by process-performance measures. The Danish Civil Registration System[@b17-clep-10-1053] established in 1968 holds data on date of birth, vital status, and migration on all individuals in Denmark. Every citizen has a unique civil personal registration number, which allows for individual-level linkage across all Danish registries. The Danish National Patient Registry[@b18-clep-10-1053] contains data on civil personal registration number, hospital admission and discharge diagnosis codes, and diagnostic and surgical procedure codes from all Danish somatic hospitals since 1977. Diagnoses were coded using the ICD-8 until the end of 1993 and ICD-10 thereafter. The Danish National Database of Reimbursed Prescriptions[@b19-clep-10-1053] tracks reimbursed medicine dispensing at all community pharmacies and hospital-based outpatient pharmacies in Denmark since 2004. The database holds data on civil personal registration number, Anatomical Therapeutic Chemical code, redemption date, item quantity, pack size, defined daily dose, dose form, and generic substitution done at pharmacy.

Participants
------------

Patients aged 65 years or older undergoing surgical treatment for hip fracture between 2004 and 2016 were identified in the Danish Multidisciplinary Hip Fracture Registry. The study period was subsequently restricted to patients registered between January 1, 2006, and December 31, 2016, to ensure at least 2 years prescription history. Patients with missing data on operation delay (n=119) were excluded. In total, 68,487 first-time hip fracture patients who received surgery from 2006--2016 were available for analyses.

Variables
=========

Exposure
--------

All redeemed prescriptions for SSRIs 1 year before hip fracture surgery were identified in the Danish National Database of Reimbursed Prescriptions. Patients were classified according to SSRI use. Current SSRI users redeemed at least one prescription within 90 days, former users redeemed one prescription between 91 and 365 days, and non-users redeemed no prescriptions within 365 days before hip fracture surgery.

Outcomes
--------

Several outcomes occurring after hip fracture surgery were examined separately. First, all-cause 30-day mortality was ascertained from the Civil Registration System. Second, postoperative complications were ascertained from the Danish National Patient Registry. The following postoperative complications were examined: 1) any unplanned readmission, 2) any reoperation, 3) cardiovascular events including VTE, MI, and stroke, and 4) major bleeding defined as intracranial bleeding, gastrointestinal bleeding, or urinary/lung bleeding within 30 days of surgery. Third, quality of in-hospital care represented by process-performance measures[@b20-clep-10-1053] including preoperative optimization, operation delay, mobilization within 24 hours postoperatively, basic mobility assessment at admission and discharge, nutritional risk assessment, osteoporosis prophylaxis, and future fall prophylaxis were obtained from the Danish Multidisciplinary Hip Fracture Registry.

Covariates
----------

Operation year, housing, BMI, fracture type, operation type, and operation delay information was assessed from the Danish Multidisciplinary Hip Fracture Registry. Four categories comprising housing information were created: own accommodation, residential institution, homeless, and unknown. Likewise, four categories based on BMI values were created: underweight (BMI \<18.5 kg/m^2^), normal weight (BMI ≥18.5 \<25 kg/m^2^), overweight or obese (BMI ≥25 kg/m^2^), and unknown. Age, gender, and marital status were obtained from the Danish Civil Registration System. Comorbidities were identified using the Danish National Patient Registry. Overall comorbidity was summarized according to the original Charlson Comorbidity Index (CCI) score. The CCI was categorized as low (score 0), medium (score 1--2), and high (score ≥3) comorbidity score, slightly modified compared with the original CCI.[@b21-clep-10-1053] The following medications were assessed from the Danish National Database of Reimbursed Prescriptions: non-steroidal anti-inflammatory drugs, corticosteroids, anticoagulants, statins, non-SSRI antidepressants, and antipsychotics. Use of each medication was defined as follows: current users redeemed one prescription within 90 days, former users redeemed one prescription between 91 and 365 days, and non-users redeemed no prescriptions within 365 days before hip fracture surgery. All codes defining study variables are available in [Tables S1](#SD2-clep-10-1053){ref-type="supplementary-material"}[](#SD3-clep-10-1053){ref-type="supplementary-material"}--[S3](#SD4-clep-10-1053){ref-type="supplementary-material"}.

Statistical methods
===================

Main analyses
-------------

Patient characteristics were tabulated according to SSRI use. All patients were followed from operation date to death, any unplanned readmission, any reoperation, cardiovascular event, bleeding event, or up to 30 days. Kaplan--Meier curves of the three SSRI exposure groups were plotted depicting the absolute mortality risk over time. The cumulative incidence of postoperative complications was estimated treating death as a competing risk. Crude and adjusted HRs with 95% CIs of death and postoperative complications within 30 days were estimated using Cox regression analysis comparing current and former SSRI users with non-users. The mortality model was evaluated for effect modification by age and gender. Readmission outcome data were only available for patients operated on from January 1, 2011 onward, thus readmission analyses were restricted to patients operated on between January 1, 2011 and December 31, 2016. RRs of quality of in-hospital care were estimated using Poisson regression analysis. The process-performance measures representing quality of in-hospital care were introduced in the Danish Multidisciplinary Hip Fracture Registry at various times. Therefore, the analyses regarding the quality of in-hospital care were performed only in hip fracture patients operated on between January 1, 2015 and December 31, 2016. Potential confounder assessment was done using a directed acyclic graph ([Figure S1](#SD1-clep-10-1053){ref-type="supplementary-material"}).[@b22-clep-10-1053] All adjusted analyses accounted for age, gender, marital status, operation year, comorbidities, other medication, and clustering by unit setting.

Sensitivity analysis
--------------------

Two sensitivity analyses were performed to test the robustness of the results. First, missing BMI values were imputed using multiple imputation (Supplementary materials).[@b23-clep-10-1053] Missing housing data were not imputed due to lack of predictors. Second, the exposure definition was changed to address potential compliance problems; current SSRI users redeemed two prescriptions within 2 years, of which one prescription was redeemed within 8 months before hip fracture, former users redeemed two prescriptions between 8 months and 2 years, and non-users redeemed one or no prescriptions within 2 years before hip fracture. The mortality analysis was repeated including BMI in the Cox regression model and employing a new exposure definition. Cox and Poisson regression analyses were performed using Stata 14 for Windows (StataCorp LP, College Station, TX, USA). The Kaplan--Meyer plot was produced using R for Windows 3.4.2 (The R Foundation for Statistical Computing, Vienna, Austria).

Results
=======

Patient characteristics
-----------------------

We identified 68,487 first-time hip fracture patients between 2006 and 2016. Of these, 13,272 (19%) were current SSRI users, 2,777 (4%) former, and 52,438 (77%) non-users. [Table 1](#t1-clep-10-1053){ref-type="table"} presents the patient characteristics according to SSRI use. The median patient age was 84 years in current users (IQR 78--89 years) and 83 years in former users (IQR 77--88 years) and non-users (IQR 77--89 years). The current and former SSRI users had higher overall comorbidity than non-users, as well as higher prevalence of cerebrovascular disease, dementia, use of non-SSRI antidepressants, and antipsychotics. Current SSRI users had a higher prevalence of anticoagulant use than both former users and non-users ([Table 1](#t1-clep-10-1053){ref-type="table"}).

In total, 13,295 patients (19%) were missing BMI data and 30,285 (44%) patients were missing housing data. From the available housing data, we observed that SSRI non-users (25,537 \[49%\]) more often lived in their own accommodation compared with current (4,412 \[33%\]) and former (1,126 \[41%\]) users. However, there was no difference in BMI distribution between the exposure groups ([Table 1](#t1-clep-10-1053){ref-type="table"}).

Mortality
---------

Overall, 7,295 hip fracture patients died within the first 30 days following hip fracture surgery. Mortality was higher in current (13%) and former (12%) users compared with non-users (10%) ([Figure 1](#f1-clep-10-1053){ref-type="fig"} and [Table 2](#t2-clep-10-1053){ref-type="table"}). Compared with nonusers, the adjusted HR was 1.16 (1.10--1.21) in current users and 1.15 (1.04--1.27) in former users ([Table 2](#t2-clep-10-1053){ref-type="table"}). We found no effect modification by age and gender of the relation between SSRI use and mortality.

Readmission and reoperation
---------------------------

[Table 2](#t2-clep-10-1053){ref-type="table"} shows cumulative incidences and HRs of any unplanned readmission and any reoperation within 30 days postoperatively. In total, 6,208 of 36,356 were readmitted and 2,327 of 68,487 re-operated within 30 days after surgery. Both current (HR 1.11, 1.02--1.20) and former users (HR 1.13, 1.01--1.27) had a higher readmission risk compared with non-users. Current SSRI users had a higher reoperation risk (HR 1.21, 1.11--1.31) compared with non-users while there was no difference between former users (HR 1.04, 0.84--1.28) and non-users.

Other postoperative complications
---------------------------------

During the first 30 days following hip fracture surgery, 573 patients experienced VTE, 546 MI, 863 stroke, and 1,011 major bleeding. [Table 2](#t2-clep-10-1053){ref-type="table"} shows cumulative incidences and HRs of the individual complications. Current SSRI users had a similar risk of VTE (HR 0.89, 0.67--1.17), MI (HR 1.03, 0.81--1.30), stroke (HR 0.93, 0.80--1.09), and bleeding (HR 1.06, 0.89--1.28) as non-users. Likewise, former SSRI users had a similar risk of VTE (HR 0.93, 0.64--1.35), MI (HR 0.89, 0.57--1.40), stroke (HR 0.67, 0.44--1.01), and bleeding (HR 1.06, 0.69--1.64) as non-users.

Quality of in-hospital care
---------------------------

The analyses included 11,363 patients operated on during 2015--2016. [Figure 2](#f2-clep-10-1053){ref-type="fig"} shows a marginally higher chance of assessment of basic mobility at discharge, osteoporosis prophylaxis, and future fall prophylaxis in former SSRI users compared with non-users. Overall, there was no association between current and former SSRI use and quality of in-hospital care ([Table S4](#SD5-clep-10-1053){ref-type="supplementary-material"}).

Sensitivity analysis
--------------------

The HRs of mortality did not materially change after multiple imputation of missing BMI values and adjustment for BMI ([Tables S5](#SD6-clep-10-1053){ref-type="supplementary-material"} and [S6](#SD7-clep-10-1053){ref-type="supplementary-material"}). Changing the exposure definition, we identified 14,530 (21%) current SSRI users, 1,116 (2%) former users, and 52,841 (77%) non-users. Patient characteristics in the new exposure groups were similar to the patient characteristics of the exposure groups used in the main analysis and the HRs of mortality were similar to the main analysis results ([Tables S7](#SD8-clep-10-1053){ref-type="supplementary-material"} and [S8](#SD9-clep-10-1053){ref-type="supplementary-material"}).

Discussion
==========

In this nationwide cohort study of hip fracture surgery patients, 30-day mortality and overall readmission were elevated for both current and former SSRI users. Those currently using SSRIs had an increased reoperation risk compared with non-users. However, SSRI use was not associated with increased risk of cardiovascular and bleeding complications and inferior quality of in-hospital care.

Strengths and limitations
-------------------------

The strengths of this study are the use of well-established, well-validated, and prospectively collected data from Danish population-based registries with complete follow-up.[@b19-clep-10-1053],[@b24-clep-10-1053]--[@b26-clep-10-1053] The registries originate from a tax-supported and uniformly organized health care system, reducing the risk of selection bias. The validity of the hip fracture diagnosis is high,[@b27-clep-10-1053],[@b28-clep-10-1053] and the complete follow-up reduces the risk of differential misclassification. In general, our study included all elderly hip fracture patients aged 65 years or older in Denmark between 2006 and 2016. These patients are similar regarding age and gender to those included in other studies on hip fractures in the elderly.[@b4-clep-10-1053],[@b7-clep-10-1053] To date, this is the largest study examining the association between SSRI use and mortality, postoperative complications, and quality of in-hospital care in hip fracture patients.

We gathered comprehensive data on potential confounders including complete in-hospital comorbidity history com piled in the CCI[@b26-clep-10-1053] and history of specific diseases. However, we did not have information on the severity of diseases included in the CCI, on diseases treated in primary care, which were not severe enough to warrant a hospital diagnosis, or information on the underlying disease indication for SSRI prescription. However, we included information on other medication, which may indicate treatment of conditions not captured in the CCI. The registries we used did not contain information on socioeconomic status, smoking, alcohol use, and other lifestyle factors. Furthermore, almost half of the patients were missing data on housing, making control of confounding difficult. Thus, we were not able to control for the potential confounding of social deprivation and lack of these data may have resulted in unmeasured and residual confounding. Information on comorbidities, other medication, marital status, and unit setting may contribute to control of confounding, but is not an adequate measure of social deprivation.

We included former SSRI users as a negative control. That is, we anticipated that former users were more similar to current users than non-users regarding potential confounding factors such as socioeconomic status and lifestyle factors. Thus, if the effect of SSRI exposure on mortality was caused by the medication itself, we would anticipate only seeing an effect in current users and not in former users. However, this was not the case, and the observed association between SSRI use and mortality may rather be caused by underlying risk factors.[@b29-clep-10-1053]

We did not have information about compliance. In our study, non-compliance would cause a misclassification of non-users as users, and therefore the observed association between SSRI use and mortality, readmission, or reoperation risk might actually be higher. However, as the patients redeemed the prescriptions, our estimates most likely reflect actual drug use. Even considering misclassification, dispensed prescriptions are considered a good measure of medication intake.[@b30-clep-10-1053] Furthermore, we had no data on in-hospital medication use. This may not have influenced the outcome since hip fracture surgery is an acute procedure with short length of hospital stay.

Comparison with other studies
-----------------------------

We observed an equally increased mortality risk in current and former SSRI users. This suggests that rather than being a risk factor in itself, SSRI use may be a marker of underlying risk factors such as psychiatric illness, socioeconomic status, and lifestyle factors (smoking, alcohol misuse, and physical inactivity). These results are consistent with those obtained by Auerbach et al, showing an increased mortality in SSRI users compared with non-users after major surgery, including approximately 2% hip fracture surgeries.[@b12-clep-10-1053] However, the association found by Auerbach et al was attenuated in patients with depression suggesting that the underlying psychiatric indication for SSRI use may explain the increased risk rather than SSRIs in itself.[@b12-clep-10-1053] A meta-analysis by Maslej et al found an increased mortality in antidepressant users compared to non-users in the general population independent of treatment indication.[@b31-clep-10-1053] The most common indications for SSRI treatment are depression and anxiety[@b10-clep-10-1053] and a systematic review by Eaton et al showed that depression and anxiety correlate with increased mortality.[@b32-clep-10-1053] Mortality in hip fracture patients may also be influenced by socioeconomic status,[@b33-clep-10-1053] and Marinacci et al found an association between lower education level and mortality.[@b34-clep-10-1053] Lower education level is further associated with increased risk of psychiatric admission due to schizophrenia, alcoholism, drug dependency, affective psychosis, neurosis, and personality disorder.[@b35-clep-10-1053] Finally, Seitz et al found no difference in 30-day mortality between current (9.1%) and former (9.4%) serotonergic antidepressant users undergoing hip fracture surgery.[@b36-clep-10-1053] However, they did not include a non-user group, which distorts the association between SSRI use and mortality.

Our findings of an increased overall readmission risk in current and former SSRI users compared with non-users is consistent with the findings reported by Auerbach et al in major surgery patients. In their study, this association persisted in patients receiving SSRIs for depression, but not in patients receiving SSRIs for other reasons.[@b12-clep-10-1053] This also suggests that SSRI use may not be a risk factor in itself but a marker of underlying disease or risk factors. A meta-analysis by Pizzi et al found no association between SSRI use and readmission in patients with coronary heart disease and depression, further supporting our results that SSRI use may not be a risk factor in itself.[@b37-clep-10-1053]

Another important finding was that current SSRI users had an increased reoperation risk compared with non-users, whereas the risk was not elevated in former users. A possible explanation for this could be that SSRI use may increase the likelihood of complications necessitating reoperation. There are different reasons for performing reoperation, eg, wound dehiscence, infection, and bleeding,[@b20-clep-10-1053] and these complications may be more frequent in SSRI users. Gärtner et al found an association between SSRI use and reoperation due to bleeding after breast cancer surgery.[@b38-clep-10-1053] However, Tully et al showed no association between serotonergic antidepressant use and reoperation due to infection or bleeding after coronary artery bypass graft surgery.[@b39-clep-10-1053] Further research is needed to establish the association between SSRI use and reoperation risk due to different causes in hip fracture patients.

We found little evidence of an association between SSRI and the risk of VTE, MI, stroke, and bleeding. To our knowledge, no other studies have investigated the association between SSRI use and the previously mentioned postoperative complications following hip fracture surgery. Auerbach et al found an association between SSRI use and postoperative bleeding in major surgery patients. However, they had a broader bleeding definition, including bleeding following procedure, and they included both acute and elective operations.[@b12-clep-10-1053] Tully et al showed no association between SSRI use and MI, stroke, or bleeding after coronary artery bypass graft surgery,[@b39-clep-10-1053] supporting our findings.

The present study did not find any difference between SSRI non-users and users regarding quality of in-hospital care. This is important and in line with efforts of European governments to reduce social inequality in treatment of patients.[@b40-clep-10-1053] However, we have no information on quality of patient care outside hospital settings. Previous research suggests lower 30-day mortality in hip fracture patients who received higher quality of care.[@b5-clep-10-1053] Quality of in-hospital care may not explain the increased mortality associated with SSRI use in our study.

Implications of findings
------------------------

One issue emerging from our findings is the question about discontinuation of SSRI treatment after hip fracture surgery. Since hip fracture is an acute condition, it is not possible to stop treatment before surgery. Our analysis suggests that stopping SSRI treatment after surgery would not change the mortality and overall readmission since these were similar in current and former users compared with non-users. We found that overall reoperation was augmented in current users, but not in former users compared with non-users. However, pausing SSRI treatment without a complete discussion of the risks and benefits is unwarranted. Our findings call for increased clinical awareness of hip fracture patients using SSRIs as they may have an increased risk of mortality, unplanned readmission, and reoperation. This patient group may be more prone to adverse outcomes after surgery regardless of the indication for SSRI treatment and may benefit from improved models of care. The follow-up care in Denmark is carried out by the municipality. Our findings suggest that hip fracture patients currently or formerly using SSRIs may benefit from closer follow-up and better communication between hospital, municipality, and general practitioner. However, the content and implementation of such improvements are beyond the scope of this paper. In future studies, it may be relevant to investigate how social deprivation influences surgical outcomes for these patients.

Conclusion
==========

Thirty-day mortality and overall readmission in hip fracture patients were elevated in both current and former SSRI users compared with non-users. Those currently using SSRIs had an increased overall reoperation risk compared with nonusers. However, SSRI use was not associated with increased risk of cardiovascular and bleeding complications and lower quality of in-hospital care.

Data availability
=================

The authors are not authorized to share the data as it were assessed via the data custodian, ie, the Danish National Data Board.

Supplementary materials
=======================

Sensitivity analyses
--------------------

### Multiple imputation

#### Methods

In the multiple imputation model, we included all variables that were in the subsequent analysis model: selective serotonin reuptake inhibitors (SSRIs), age, gender, marital status, operation year, BMI, comorbidities, and other medication. Further more, some auxiliary variables such as operation delay, fracture type, operation type, and postoperative complications were included. Imputation of BMI values was done using truncated regression creating 20 imputed datasets. After imputation, the association between SSRI use and mortality was estimated in each imputed dataset. The measures of association from each imputed dataset were combined using Rubin's rule.

###### 

Directed acyclic graph of the possible relationship between important covariates and mortality in hip fracture patients.

**Abbreviations:** SSRI, selective serotonin reuptake inhibitor; CCI, Charlson Comorbidity Index.

###### 

ICD-8 and ICD-10 diagnosis codes from the Danish National Patient Registry

  Variable                                                       Codes                                                                                                           
  -------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------
  Myocardial infarction                                          410                                                                                                             I21; I22; I23
  Congestive heart failure                                       427.09; 427.10; 427.11; 427.19; 428.99; 782.49                                                                  I50; I11.0; I13.0; I13.2
  Peripheral vascular disease                                    440; 441; 442; 443; 444; 445                                                                                    I70; I71; I72; I73; I74; I77
  Cerebrovascular disease                                        430--438                                                                                                        I60-I69; G45; G46
  Dementia                                                       290.09--290.19; 293.09                                                                                          F00-F03; F05.1; G30
  Chronic pulmonary disease                                      490--493; 515--518                                                                                              J40-J47; J60-J67; J68.4; J70.1; J70.3; J84.1; J92.0; J96.1; J98.2; J98.3
  Connective tissue disease                                      712; 716; 734; 446; 135.99                                                                                      M05; M06; M08; M09; M30; M31; M32; M33; M34; M35; M36; D86
  Ulcer disease                                                  530.91; 530.98; 531--534                                                                                        K22.1; K25-K28
  Liver disease                                                  571; 573.01; 573.04; 070.00; 070.02; 070.04; 070.06; 070.08; 573.00; 456.00--456.09                             B18; K70.0-K70.3; K70.9; K71; K73; K74; K76.0; B15.0; B16.0; B16.2; B19.0; K70.4; K72; K76.6; I85
  Diabetes type 1 and type 2                                     249.00; 249.06; 249.07; 249.09 250.00; 250.06; 250.07; 250.09; 249.01--249.05; 249.08; 250.01--250.05; 250.08   E10.0, E10.1; E10.9 E11.0; E11.1; E11.9; E10.2-E10.8; E11.2-E11.8
  Hemiplegia                                                     344                                                                                                             G81; G82
  Moderate to severe renal                                       403; 404; 580--583; 584; 590.09;                                                                                I12; I13; N00-N05; N07; N11; N14;
  disease                                                        593.19; 753.10--753.19; 792                                                                                     N17-N19; Q61
  Cancer                                                         140--194; 204--207; 200--203; 275.59; 195--198; 199                                                             C00--C75; C91--C95; C81--C85; C88; C90; C96; C76--C80
  Intracranial bleeding                                                                                                                                                          I60--I62
  Esophagus varices with bleeding                                                                                                                                                I850
  Hemothorax                                                                                                                                                                     J942
  Acute ulcer with bleeding                                                                                                                                                      K250, K260, K270, K280
  Acute ulcer with bleeding and perforation                                                                                                                                      K252, K262, K272, K282
  Chronic or non-specified ulcer with bleeding                                                                                                                                   K254, K264, K274, K284
  Chronic or non-specified ulcer with bleeding and perforation                                                                                                                   K256, K266, K276, K286
  Acute bleeding gastritis                                                                                                                                                       K290
  Bleeding from anus or rectum                                                                                                                                                   K625
  Gastrointestinal bleeding                                                                                                                                                      K920--K922
  Hematuria                                                                                                                                                                      R31, N02
  Airway bleeding                                                                                                                                                                R04
  Deep venous thromboembolism                                                                                                                                                    I801--I803
  Lung embolism                                                                                                                                                                  I26
  Acute myocardial infarction                                                                                                                                                    I21
  Brain infarction                                                                                                                                                               I63
  Apoplexy, unspecified                                                                                                                                                          I64
  Transitory cerebral infarction                                                                                                                                                 G459

###### 

Codes from the Danish Multidisciplinary Hip Fracture Registry

  Description                                                                                        Codes
  -------------------------------------------------------------------------------------------------- ------------------------------------------------
  **Housing**                                                                                        
   Procedure code specifying housing                                                                 ZZ8050
   Own accommodation                                                                                 ZRSB01
   Own accommodation in association with an institution                                              ZRSB01A
   Homeless                                                                                          ZRSB02
   Residential institution                                                                           ZRSB04
   No information on housing                                                                         ZRSB09
  **Fracture type**                                                                                  
   Fracture of the femoral neck                                                                      S72.0
   Pertrochanteric fracture                                                                          S72.1
   Subtrochanteric fracture                                                                          S72.2
  **Operation type**                                                                                 
   Primary insertion of joint prosthesis in hip joint                                                KNFB.0--99
   Fracture treatments in femur (including osteosynthesis)                                           KNFJ.4--9
  **BMI**                                                                                            
   Procedure code determining BMI                                                                    ZZ0242
   BMI 10--80                                                                                        VPH0010 -- VPH0080
   BMI 10--80                                                                                        VPK10K00 -- VPK80K00
  **Assessment of the patient's nutritional risk**                                                   
   Preparation of nutritional plan                                                                   ZZ2009C
   Assessment: no indication for preparation of nutritional plan                                     ZZ2009D
  **Systematic pain assessment during mobilization of the patient**                                  
   Systematic assessment of pain using pain scale                                                    ZZV008A
   Pain assessment attempted: not possible                                                           ZZV008Z
  **Early mobilization within 24 hours of surgery**                                                  
   Early mobilization commenced                                                                      ZZP0030A
   Assessed, no indication for early mobilization                                                    ZZP0030C
   Date of mobilization (eg, ZT20160602)                                                             ZT[a](#tfn5-clep-10-1053){ref-type="table-fn"}
   Time of mobilization (eg, ZU1430)                                                                 ZU[a](#tfn5-clep-10-1053){ref-type="table-fn"}
  **Assessment of basic mobility before admission for hip fracture**                                 
   Assessment of the basic mobility prior to fracture                                                ZZV020G1
   Cumulated Ambulation Score (CAS)                                                                  ZRRA00 -- ZRRA09
  **Assessment of basic mobility before discharge**                                                  
   Assessment of basic mobility at discharge                                                         ZZV020G2
   CAS                                                                                               ZRRA00 -- ZRRA09
  **Initiation of rehabilitation program**                                                           
   Preparation of rehabilitation plan, general rehabilitation                                        ZZ0175X
   Preparation of rehabilitation plan, specialized rehabilitation                                    ZZ0175Y
   Preparation of rehabilitation plan, rehabilitation in the specialized level                       ZZ0175V
   Assessment of need for rehabilitation, no rehabilitation                                          ZZ0172W
  **Osteoporosis prophylaxis**                                                                       
   Treatment with medicine for osteoporosis                                                          BLHM7
   Evaluation of the indication for drug therapy for osteoporosis                                    ZZV010A1A
   Pending complete investigation regarding indication for drug therapy for osteoporosis             ZZV010A1X
  **Fall prophylaxis**                                                                               
   Offer of fall prophylaxis given                                                                   ZZ5707B1
   Assessment of need for fall prophylaxis: no indication                                            ZZ5707A
  **Surgery delay**                                                                                  
   Indicates the percentage of patients who are operated on within 24 hours of arrival at hospital   2A
   Indicates the percentage of patients who are operated on within 36 hours of arrival at hospital   2B

**Note:**

Number specifying the date or time of mobilization.

###### 

Anatomical Therapeutic Chemical (ATC) codes from the Danish National Database of Reimbursed Prescriptions

  Selective serotonin reuptake inhibitor (SSRI)   ATC codes
  ----------------------------------------------- ----------------------------
   Citalopram                                     N06AB04
   Escitalopram                                   N06AB10
   Fluoxetine                                     N06AB03
   Fluvoxamine                                    N06AB08
   Paroxetine                                     N06AB05
   Sertraline                                     N06AB06
  **Other medication**                            
   Non-SSRI antidepressants                       N06AA, N06AF, N06AG, N06AX
   Antipsychotics                                 N05A
   Antithrombotic medicine                        B01A
   Non-steroidal anti-inflammatory drugs          M01A
   Corticosteroids                                H02AB
   Statins                                        C10AA

###### 

Unadjusted and adjusted RRs with 95% CIs of quality of in-hospital care according to selective serotonin reuptake inhibitor (SSRI) use 2015--2016 (N=11,363)

                                      Fulfilment (%)      Unadjusted RR (95% CI)   Adjusted[a](#tfn6-clep-10-1053){ref-type="table-fn"} RR (95% CI)
  ----------------------------------- ------------------- ------------------------ ------------------------------------------------------------------
  **Preoperative optimization**       **4,301 (37.9)**                             
   Current user                       649 (37.2)          0.98 (0.90--1.07)        1.00 (0.93--1.07)
   Former user                        161 (37.0)          0.97 (0.83--1.14)        0.97 (0.88--1.09)
   Non-user                           3,491 (38.0)        1.00                     1.00
  **Surgery within 24 hours**         **7,751 (68.2)**                             
   Current user                       1,175 (67.4)        0.99 (0.93--1.05)        1.00 (0.97--1.04)
   Former user                        291 (66.9)          0.98 (0.87--1.10)        1.00 (0.94--1.06)
   Non-user                           6,285 (68.4)        1.00                     1.00
  **Surgery within 36 hours**         **9,641 (84.8)**                             
   Current user                       1,471 (84.4)        0.99 (0.94--1.05)        1.00 (0.98--1.02)
   Former user                        354 (81.4)          0.96 (0.86--1.06)        0.97 (0.93--1.00)
   Non-user                           7,816 (85.1)        1.00                     1.00
  **Mobilization within 24 hours**    **6,483 (57.1)**                             
   Current user                       952 (54.6)          0.95 (0.89--1.02)        0.99 (0.94--1.03)
   Former user                        249 (57.2)          1.00 (0.88--1.13)        1.03 (0.95--1.11)
   Non-user                           5,282 (57.5)        1.00                     1.00
  **Basic mobility at admission**     **10,383 (91.4)**                            
   Current user                       1,569 (90.0)        0.98 (0.93--1.04)        0.99 (0.97--1.01)
   Former user                        402 (92.4)          1.01 (0.91--1.12)        1.02 (1.00--1.03)
   Non-user                           8,412 (91.6)        1.00                     1.00
  **Basic mobility at discharge**     **9,945 (87.5)**                             
   Current user                       1,521 (97.3)        1.00 (0.94--1.05)        1.00 (0.99--1.02)
   Former user                        391 (89.9)          1.03 (0.93--1.14)        1.03 (1.01--1.06)
   Non-user                           8,033 (87.5)        1.00                     1.00
  **Nutritional status assessment**   **9,304 (81.9)**                             
   Current user                       1,449 (83.1)        1.02 (0.96--1.08)        1.02 (0.99--1.06)
   Former user                        344 (79.1)          0.97 (0.87--1.08)        0.97 (0.91--1.03)
   Non-user                           7,511 (81.8)        1.00                     1.00
  **Osteoporosis prophylaxis**        **9,673 (85.1)**                             
   Current user                       1,476 (84.7)        1.00 (0.94--1.05)        1.00 (0.98--1.03)
   Former user                        392 (90.1)          1.06 (0.96--1.17)        1.07 (1.03--1.11)
   Non-user                           7,805 (85.0)        1.00                     1.00
  **Future fall prophylaxis**         **9,402 (82.7)**                             
   Current user                       1,431 (82.1)        0.99 (0.94--1.05)        1.00 (0.97--1.03)
   Former user                        380 (87.4)          1.06 (0.95--1.17)        1.06 (1.02--1.11)
   Non-user                           7,591 (82.7)        1.00                     1.00

**Notes:**

Adjusted for age, gender, marital status, operation year, myocardial infarction, congestive heart failure, peripheral vascular disease, dementia, chronic pulmonary disease, connective tissue disease, ulcer disease, liver disease, diabetes type 1 and 2, hemiplegia, moderate to severe renal disease, cancer, non-steroidal anti-inflammatory drugs, corticosteroids, anticoagulants, statins, non-SSRI antidepressants, antipsychotics, and clustering by unit setting. The numbers in bold represent the total number of patients fulfilling each process-performance measure.

###### 

Baseline characteristics of hip fracture patients (n=68,487) according to preoperative selective serotonin reuptake inhibitor (SSRI) use 2006--2016 after imputation of BMI

  Variables                                                       All patients   SSRI                                            
  --------------------------------------------------------------- -------------- ------- -------- ------ ------- ------ -------- -------
  **Total**                                                       68,487         100     52,438   76.6   2,777   4.0    13,272   19.4
  **Median age (years)**                                          83                     83              83             84       
  **Age (years)**                                                                                                                
   65--74                                                         13,271         19.4    10,571   20.2   533     19.2   2,167    16.3
   75--84                                                         26,086         38.1    19,768   37.7   1,159   41.7   5,159    38.9
   ≥85                                                            29,130         42.5    22,099   42.1   1,085   39.1   5,946    44.8
  **Gender**                                                                                                                     
   Male                                                           19,750         28.8    15,541   29.6   730     26.3   3,479    26.2
   Female                                                         48,737         71.2    36,897   70.4   2,047   73.7   9,793    73.8
  **Marital status**                                                                                                             
   Married                                                        20,300         29.6    16,105   30.7   842     30.3   3.353    25.3
   Unmarried                                                      48,187         70.4    36,333   69.3   1,935   69.7   9,919    74.7
  **Housing**                                                                                                                    
   Own accommodation                                              31,075         45.4    25,537   48.7   1,126   40.5   4,412    33.2
   Homeless                                                       22             \<0.1   20       0.1    0       0.0    2        \<0.1
   Residential institution                                        7,105          10.4    4,213    8.0    408     14.7   2,484    18.7
   Unknown                                                        30,285         44.2    22,668   43.2   1,243   44.8   6,374    48.0
  **Fracture type**                                                                                                              
   Fracture of femoral neck                                       36,341         53.1    27,854   53.1   1,451   52.3   7,036    53.0
   Per- and subtrochanteric fracture                              32,146         46.9    24,584   46.9   1,326   47.7   6,236    46.9
  **Operation type**                                                                                                             
   Alloplastic surgery                                            46,859         68.4    35,843   68.4   1,902   68.5   9,114    68.7
   Osteosynthesis                                                 21,628         31.6    16,595   31.6   875     31.5   4,158    31.3
  **Operation delay (hours)**                                                                                                    
   \<24                                                           41,671         60.8    31,859   60.8   1,721   62.0   8,091    61.0
   24--48                                                         12,517         18.3    9,646    18.4   461     16.6   2,410    18.1
   \>48                                                           14,299         20.9    10,933   20.8   595     21.4   2,771    20.9
  **Operation year**                                                                                                             
   2006--2010                                                     32,131         46.9    23,822   45.4   1,342   48.3   6,967    52.5
   2011--2016                                                     36,356         53.1    28,616   54.6   1,435   51.7   6,305    47.5
  **BMI (kg/m^2^)**[a](#tfn7-clep-10-1053){ref-type="table-fn"}                                                                  
   \<18.5: underweight                                            7,672          11.2    5,806    11.1   357     12.9   1,509    11.4
   ≥18.5 \<25: normal weight                                      35,397         51.7    27,163   51.8   1,440   51.8   6,794    51.2
   ≥25: overweight or obese                                       25,418         37.1    19,469   37.1   980     35.3   4,969    37.4
  **Charlson Comorbidity Index**                                                                                                 
   Low (0)                                                        27,283         39.8    22,505   42.9   840     30.3   3,938    29.7
   Medium (1--2)                                                  27,787         40.6    20,365   38.8   1,244   44.8   6,178    46.5
   High (3+)                                                      13,417         19.6    9,568    18.3   693     24.9   3,156    23.8
  **Comorbidity**                                                                                                                
   Myocardial infarction                                          3,762          5.5     2,820    5.4    151     5.4    791      6.0
   Congestive heart failure                                       6,289          9.2     4,632    8.8    291     10.5   1,366    10.3
   Peripheral vascular disease                                    5,511          8.1     4,060    7.7    267     9.6    1,184    8.9
   Cerebrovascular disease                                        12,678         18.5    8,467    16.2   689     24.8   3,522    26.5
   Dementia                                                       6,733          9.8     3,859    7.4    433     15.6   2,441    19.4
   Chronic pulmonary disease                                      8,663          12.7    6,191    11.8   496     17.9   1,976    14.9
   Connective tissue disease                                      3,243          4.7     2,480    4.7    139     5.0    624      4.7
   Ulcer disease                                                  3,855          5.6     2,673    5.1    224     8.1    958      7.2
   Liver disease                                                  870            1.3     646      1.2    46      1.7    178      1.3
   Diabetes type 1 and 2                                          6,689          9.8     5,005    9.5    281     10.1   1,403    10.6
   Hemiplegia                                                     175            0.3     111      0.2    12      0.4    52       0.4
   Moderate to severe renal disease                               2,688          3.9     1,973    3.4    132     4.8    583      4.4
   Cancer                                                         10,957         16.0    8,351    15.9   501     18.0   2,105    15.9
  **Other medication**                                                                                                           
   NSAIDs                                                         7,681          11.2    5,869    11.2   334     12.0   1,478    11.1
   Corticosteroids                                                4,158          6.1     3,068    5.9    186     6.7    904      6.8
   Anticoagulants                                                 26,716         39.0    19,323   36.9   1,064   38.3   6,329    47.7
   Statins                                                        13,052         19.1    9,581    18.3   505     19.2   2,966    22.4
   Other antidepressants                                          7,975          11.6    4,977    9.5    596     21.5   2,402    18.1
   Antipsychotics                                                 4,992          7.3     2,899    5.5    319     11.5   1,774    13.4

**Note:**

BMI values from m =1 data.

**Abbreviation:** NSAIDs, non-steroidal anti-inflammatory drugs.

###### 

Incidences and HRs with 95% CIs of mortality within 30 days of hip fracture surgery according to selective serotonin reuptake inhibitor (SSRI) use 2006--2016 (N=68,487) after imputation of BMI

                 Events   Incidence (95% CI)   Unadjusted HR (95% CI)   Adjusted[a](#tfn9-clep-10-1053){ref-type="table-fn"} HR (95% CI)
  -------------- -------- -------------------- ------------------------ ------------------------------------------------------------------
  Current user   1,755    13.2 (12.7--12.8)    1.35 (1.28--1.43)        1.16 (1.10--1.22)
  Former user    338      12.2 (11.0--12.5)    1.24 (1.11--1.38)        1.12 (1.00--1.24)
  Non-user       5,202    9.9 (9.7--10.2)      1.00                     1.00

**Notes:**

Adjusted for age, gender, marital status, BMI, operation year, myocardial infarction, congestive heart failure, peripheral vascular disease, dementia, chronic pulmonary disease, connective tissue disease, ulcer disease, liver disease, diabetes type 1 and 2, hemiplegia, moderate to severe renal disease, cancer, non-steroidal anti-inflammatory drugs, corticosteroids, anticoagulants, statins, non-SSRI antidepressants, antipsychotics, and clustering by unit setting.

###### 

Baseline characteristics of hip fracture patients (n=68,487) according to preoperative selective serotonin reuptake inhibitor (SSRI) use 2006--2016 after changing the exposure definition

  Variables                            All patients   SSRIs                                            
  ------------------------------------ -------------- ------- -------- ------- ------- ------ -------- -------
  **Total**                            68,487         100     52,841   77.2    1,116   1.6    14,530   21.2
  **Median age (years)**               83                     83               82             84       
  **Age (years)**                                                                                      
   65--74                              13,271         19.4    10,620   20.1    230     20.6   2,421    16.6
   75--84                              26,086         38.1    19,910   37.7    487     43.6   5,689    39.2
   ≥85                                 29,130         42.5    22,311   42.2    399     35.8   6,420    44.2
  **Gender**                                                                                           
   Male                                19,750         28.8    15,690   29.7    274     24.5   3,786    26.1
   Female                              48,737         71.2    37,151   70.3    842     75.5   10,744   73.9
  **Marital status**                                                                                   
   Married                             20,300         29.6    16,247   30.7    320     28.7   3,733    25.7
   Unmarried                           48,187         70.4    36,594   69.3    796     71.3   10,797   74.3
  **Housing**                                                                                          
   Own accommodation                   31,075         45.4    25,728   48.7    414     37.1   4,933    33.9
   Homeless                            22             \<0.1   17       \<0.1   3       0.3    2        \<0.1
   Residential institution             7,150          10.4    4,232    8.0     190     17.0   2,683    18.5
   Unknown                             30,285         44.2    22,864   43.3    509     45.6   6,912    47.6
  **Fracture type**                                                                                    
   Fracture of femoral neck            36,341         53.1    28.073   53.1    595     53.3   7.673    52.8
   Per- and subtrochanteric fracture   32,146         46.9    24,768   46.9    521     46.7   6,857    47.2
  **Operation type**                                                                                   
   Alloplastic surgery                 46,859         68.4    36,122   68.4    761     68.2   9,976    68.7
   Osteosynthesis                      21,628         31.6    16,719   31.6    355     31.8   4,554    31.3
  **Operation delay (hours)**                                                                          
   \<24                                41,671         60.8    32,090   60.7    700     62.7   8,881    61.1
   24--48                              12,517         18.3    9,715    18.4    196     17.6   2,606    17.9
   \>48                                14,299         20.9    11,036   20.9    220     19.7   3,043    21.0
  **Operation year**                                                                                   
   2006--2010                          32,131         46.9    24,061   45.5    539     48.3   7,531    51.8
   2011--2016                          36,356         53.1    28,780   54.5    577     51.7   6,999    48.2
  **BMI (kg/m^2^)**                                                                                    
   \<18.5: underweight                 5,988          8.8     4,623    8.7     104     9.3    1,261    8.7
   ≥18.5 \<25: normal weight           31,582         46.1    24,630   46.6    492     44.1   6,460    44.5
   ≥25: overweight or obese            17,622         25.7    13,616   25.8    292     26.2   3,714    25.5
   Unknown                             13,295         19.4    9,972    18.9    228     20.4   3,095    21.3
  **Charlson Comorbidity Index**                                                                       
   Low (0)                             27,283         39.8    22,655   42.9    339     30.4   4,289    29.5
   Medium (1--2)                       27,787         40.6    20,544   38.9    494     44.3   6,749    46.5
   High (3+)                           13,417         19.6    9,642    18.2    283     25.3   3,492    24.0
  **Comorbidity**                                                                                      
   Myocardial infarction               3,762          5.5     2,848    5.4     57      5.1    857      5.9
   Congestive heart failure            6,289          9.2     4,677    8.9     125     11.2   1,487    10.2
   Peripheral vascular disease         5,511          8.1     4,092    7.7     112     10.0   1,307    9.0
   Cerebrovascular disease             12,678         18.5    8,549    16.2    278     24.9   3,851    26.5
   Dementia                            6,733          9.8     3,891    7.4     172     15.4   2,670    18.4
   Chronic pulmonary disease           8,663          12.7    6,229    11.8    187     16.8   2,247    15.5
   Connective tissue disease           3,243          4.7     2,495    4.7     60      5.4    688      4.7
   Ulcer disease                       3,855          5.6     2,693    5.1     81      7.3    1,081    7.4
   Liver disease                       870            1.3     647      1.2     24      2.2    199      1.4
   Diabetes type 1 and 2               6,689          9.8     5,041    9.5     131     11.7   1,517    10.4
   Hemiplegia                          175            0.3     112      0.2     3       0.3    60       0.4
   Moderate to severe renal disease    2,688          3.9     1,995    3.8     54      4.8    639      4.4
   Cancer                              10,957         16.0    8,440    16.0    175     15.7   2,342    16.1
  **Other medication**                                                                                 
   NSAIDs                              7,681          11.2    5,926    11.2    128     11.5   1,627    11.2
   Corticosteroids                     4,158          6.1     3,100    5.9     86      7.7    972      6.7
   Anticoagulants                      26,716         39.0    19,520   36.9    425     38.1   6,771    46.6
   Statins                             13,052         19.1    9,698    18.4    182     16.3   3,172    21.8
   Other antidepressants               7,975          11.6    4,905    9.3     372     33.3   2,698    18.6
   Antipsychotics                      4,992          7.3     2,897    5.5     165     14.8   1,930    13.3

**Abbreviation:** NSAIDs, non-steroidal anti-inflammatory drugs.

###### 

Incidences and HRs with 95% CIs of mortality within 30 days of hip fracture surgery according to selective serotonin reuptake inhibitor (SSRI) use 2006--2016 (N=68,487) after changing the exposure definition

                 Events   Incidence (95% CI)   Unadjusted HR (95% CI)   Adjusted[a](#tfn11-clep-10-1053){ref-type="table-fn"} HR (95% CI)
  -------------- -------- -------------------- ------------------------ -------------------------------------------------------------------
  Current user   1,907    13.1 (12.6--13.7)    1.34 (1.27--1.41)        1.16 (1.10--1.21)
  Former user    137      12.3 (10.5--14.4)    1.25 (1.05--1.48)        1.12 (0.97--1.30)
  Non-user       5,251    9.9 (9.7--10.2)      1.00                     1.00

**Notes:**

Adjusted for age, gender, marital status, operation year, myocardial infarction, congestive heart failure, peripheral vascular disease, dementia, chronic pulmonary disease, connective tissue disease, ulcer disease, liver disease, diabetes type 1 and 2, hemiplegia, moderate to severe renal disease, cancer, non-steroidal anti-inflammatory drugs, corticosteroids, anticoagulants, statins, non-SSRI antidepressants, antipsychotics, and clustering by unit setting.
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![Kaplan--Meyer survival curve showing mortality in hip fracture patients according to selective serotonin reuptake inhibitor (SSRI) use 2006--2016.](clep-10-1053Fig1){#f1-clep-10-1053}

![Adjusted RRs with 95% CIs of quality of in-hospital care comparing current and former selective serotonin reuptake inhibitor (SSRI) users with non-users (reference) 2015--2016 (N=11,363).\
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###### 

Baseline characteristics of hip fracture patients (n=68,487) according to preoperative selective serotonin reuptake inhibitor use 2006--2016

  -----------------------------------------------------------------------------------------------------------------
  Characteristics                      All patients\   SSRI status                                          
                                       (N=68,487)                                                           
  ------------------------------------ --------------- ------------- -------- ------ ------- ------ ------- -------
  **Age (years)**                                                                                           

   65--74                              13,271          19.4          10,571   20.2   533     19.2   2,167   16.3

   75--84                              26,086          38.1          19,768   37.7   1,159   41.7   5,159   38.9

   ≥85                                 29,130          42.5          22,099   42.1   1,085   39.1   5,946   44.8

  **Gender**                                                                                                

   Male                                19,750          28.8          15,541   29.6   730     26.3   3,479   26.2

   Female                              48,737          71.2          36,897   70.4   2,047   73.7   9,793   73.8

  **Marital status**                                                                                        

   Married                             20,300          29.6          16,105   30.7   842     30.3   3.353   25.3

   Unmarried                           48,187          70.4          36,333   69.3   1,935   69.7   9,919   74.7

  **Housing**                                                                                               

   Own accommodation                   31,075          45.4          25,537   48.7   1,126   40.5   4,412   33.2

   Homeless                            22              \<0.1         20       0.1    0       0.0    2       \<0.1

   Residential institution             7,105           10.4          4,213    8.0    408     14.7   2,484   18.7

   Unknown                             30,285          44.2          22,668   43.2   1,243   44.8   6,374   48.0

  **Fracture type**                                                                                         

   Fracture of femoral neck            36,341          53.1          27,854   53.1   1,451   52.3   7,036   53.0

   Per- and subtrochanteric fracture   32,146          46.9          24,584   46.9   1,326   47.7   6,236   46.9

  **Operation type**                                                                                        

   Alloplastic surgery                 46,859          68.4          35,843   68.4   1,902   68.5   9,114   68.7

   Osteosynthesis                      21,628          31.6          16,595   31.6   875     31.5   4,158   31.3

  **Operation delay (hours)**                                                                               

   \<24                                41,671          60.8          31,859   60.8   1,721   62.0   8,091   61.0

   24--48                              12,517          18.3          9,646    18.4   461     16.6   2,410   18.1

   \>48                                14,299          20.9          10,933   20.8   595     21.4   2,771   20.9

  **Operation year**                                                                                        

   2006--2010                          32,131          46.9          23,822   45.4   1,342   48.3   6,967   52.5

   2011--2016                          36,356          53.1          28,616   54.6   1,435   51.7   6,305   47.5

  **BMI (kg/m^2^)**                                                                                         

  \<18.5: underweight                  5,988           8.8           4,558    8.7    292     10.5   1,138   8.6

   ≥18.5 \<25: normal weight           31,582          46.1          24,390   46.5   1,254   45.2   5,938   44.7

   ≥25: overweight or obese            17,622          25.7          13,602   25.9   689     24.8   3,331   25.1

   Unknown                             13,295          19.4          9,888    18.9   542     19.5   2,865   21.6

  **Charlson Comorbidity Index**                                                                            

   Low (0)                             27,283          39.8          22,505   42.9   840     30.3   3,938   29.7

   Medium (1--2)                       27,787          40.6          20,365   38.8   1,244   44.8   6,178   46.5

   High (3+)                           13,417          19.6          9,568    18.3   693     24.9   3,156   23.8

  **Comorbidity**                                                                                           

   Myocardial infarction               3,762           5.5           2,820    5.4    151     5.4    791     6.0

   Congestive heart failure            6,289           9.2           4,632    8.8    291     10.5   1,366   10.3

   Peripheral vascular disease         5,511           8.1           4,060    7.7    267     9.6    1,184   8.9

   Cerebrovascular disease             12,678          18.5          8,467    16.2   689     24.8   3,522   26.5

   Dementia                            6,733           9.8           3,859    7.4    433     15.6   2,441   19.4

   Chronic pulmonary disease           8,663           12.7          6,191    11.8   496     17.9   1,976   14.9

   Connective tissue disease           3,243           4.7           2,480    4.7    139     5.0    624     4.7

   Ulcer disease                       3,855           5.6           2,673    5.1    224     8.1    958     7.2

   Liver disease                       870             1.3           646      1.2    46      1.7    178     1.3

   Diabetes type 1 and 2               6,689           9.8           5,005    9.5    281     10.1   1,403   10.6

   Hemiplegia                          175             0.3           111      0.2    12      0.4    52      0.4

   Moderate to severe renal disease    2,688           3.9           1,973    3.4    132     4.8    583     4.4

   Cancer                              10,957          16.0          8,351    15.9   501     18.0   2,105   15.9

   NSAIDs                              7,681           11.2          5,869    11.2   334     12.0   1,478   11.1

   Corticosteroids                     4,158           6.1           3,068    5.9    186     6.7    904     6.8

   Anticoagulants                      26,716          39.0          19,323   36.9   1,064   38.3   6,329   47.7

   Statins                             13,052          19.1          9,581    18.3   505     19.2   2,966   22.4

   Non-SSRI antidepressants            7,975           11.6          4,977    9.5    596     21.5   2,402   18.1

   Antipsychotics                      4,992           7.3           2,899    5.5    319     11.5   1,774   13.4
  -----------------------------------------------------------------------------------------------------------------

**Abbreviations:** SSRI, selective serotonin reuptake inhibitor; NSAIDs, non-steroidal anti-inflammatory drugs.

###### 

Cumulative incidences and HRs with 95% CIs of mortality, readmission, reoperation, and postoperative complications within 30 days of hip fracture surgery according to selective serotonin reuptake inhibitor (SSRI) use 2006--2016 (N=68,487)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                Event/total    Incidence %\        Unadjusted HR\      Adjusted[a](#tfn2-clep-10-1053){ref-type="table-fn"} HR\
                                                                               (95% CI)            (95% CI)            (95% CI)
  ------------------------------------------------------------- -------------- ------------------- ------------------- ----------------------------------------------------------
  **Mortality**                                                                                                        

   Current users                                                1,755/13,272   13.2 (12.7--12.8)   1.35 (1.28--1.43)   1.16 (1.10--1.21)

   Former users                                                 338/2,777      12.2 (11.0--12.5)   1.24 (1.11--1.38)   1.15 (1.04--1.27)

   Non-users                                                    5,202/52,438   9.9 (9.7--10.2)     1.00                1.00

  **Readmission**[b](#tfn3-clep-10-1053){ref-type="table-fn"}                                                          

   Current users                                                1,192/6,305    19.0 (18.0--19.9)   1.21 (1.14--1.29)   1.11 (1.02--1.20)

   Former users                                                 280/1,435      19.6 (17.5--21.6)   1.24 (1.10--1.40)   1.13 (1.01--1.27)

   Non-users                                                    4,642/28,616   16.3 (15.8--16.7)   1.00                1.00

  **Reoperation**                                                                                                      

   Current users                                                749/13,272     5.6 (5.3--6.0)      1.29 (1.18--1.40)   1.21 (1.11--1.31)

   Former users                                                 135/2,777      4.9 (4.1--5.7)      1.10 (0.92--1.30)   1.04 (0.84--1.28)

   Non-users                                                    2,353/52,438   4.5 (4.3--4.7)      1.00                1.00

  **VTE**                                                                                                              

   Current users                                                96/13,272      0.7 (0.6--0.9)      0.85 (0.68--1.06)   0.89 (0.67--1.17)

   Former users                                                 22/2,777       0.8 (0.5--1.7)      0.92 (0.60--1.42)   0.93 (0.64--1.35)

   Non-users                                                    455/52,438     0.9 (0.8--0.9)      1.00                1.00

  **MI**                                                                                                               

   Current users                                                109/13,272     0.8 (0.7--1.0)      1.04 (0.84--1.28)   1.03 (0.81--1.30)

   Former users                                                 18/2,777       0.6 (0.4--1.0)      0.82 (0.51--1.31)   0.89 (0.57--1.40)

   Non-users                                                    419/52,438     0.8 (0.7--0.9)      1.00                1.00

  **Stroke**                                                                                                           

   Current users                                                176/13,272     1.3 (1.1--1.5)      1.06 (0.90--1.25)   0.93 (0.80--1.09)

   Former users                                                 25/2,777       0.9 (0.6--1.3)      0.72 (0.48--1.07)   0.67 (0.44--1.01)

   Non-users                                                    662/52,438     1.3 (1.2--1.4)      1.00                1.00

  **Bleeding**                                                                                                         

   Current users                                                218/13,272     1.6 (1.4--1.9)      1.17 (1.01--1.36)   1.06 (0.89--1.28)

   Former users                                                 43/2,777       1.5 (1.1--2.1)      1.09 (0.81--1.49)   1.06 (0.69--1.64)

   Non-users                                                    750/52,438     1.4 (1.3--1.5)      1.00                1.00
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Adjusted for age, gender, marital status, operation year, MI, congestive heart failure, peripheral vascular disease, dementia, chronic pulmonary disease, connective tissue disease, ulcer disease, liver disease, diabetes type 1 and 2, hemiplegia, moderate to severe renal disease, cancer, non-steroidal anti-inflammatory drugs, corticosteroids, anticoagulants, statins, non-SSRI antidepressants, antipsychotics, and clustering by unit setting.

Restricted to hip fracture patients operated on between 2011 and 2016.

**Abbreviations:** VTE, venous thromboembolism; MI, myocardial infarction.
